Anybody else out there interested in these?

2002 Results are due in April, and they are expected to show a maiden profit.
Last week I opened a small speculative long (spreadbet), but I am looking to add to this position a lot more if we get any sort of resolution over Iraq crisis before the results which should spark a broad market rally from which SKP could really benefit and have a strong run-up.

DYOR etc.


Here is a recent research note from Merrill Lynch (they estimate 0.25p EPS for 2002):


Merrill Lynch FlashNote

7 February 2003

SkyePharma

Newsflow Set To Continue BUY

Reason for Report: Company Update

EPS (Dec): 2001A -1.19p; 2002E 0.25p; 2003E 2.13p
P/E (Dec): 2001A NM; 2002E 180.0x; 2003E 21.1x

Michael Ashton, CEO SkyePharma, gave an upbeat and informative presentation today.

Depomorphine appears on track for US submission in June 03. The two pivotal trials (hip and lower abdominal surgery) have been concluded. To date, the results appear encouraging. Management believe that safety (eg respiratory depression and nausea) is not an issue for the drug.The company is also conducting an additional trial in C section patients which is completing enrollment and should be included in the European submission for Depomorphine later this year. We expect the pivotal trial data for Depomorphine to be presented at the American Society of Clinical Anaesthesiologists in October 2003.

Paxil CR continues to grow (accounting for c.26% of total Paxil scrips in the US). 50% of these Paxil CR scrips are repeat and Paxil CR accounts for c.7% of the total SSRI antidepressant market in the US. Paxil CR is already filed for pre-menstrual dysphoria disorder (PMDD). However, GSK also plans to submit the intermittent treatment of PMDD later this year.

SKP also confirmed that Quintiles plans to present new data for Solaraze at the American Society of Dermatology in March. SKP believes that Solaraze is making in-roads into the actinic keratosis market and appears to be taking market share from Ephedrex (5-FU). Clinical trials in Australia are on track, with SKP planning to submit Solaraze to the Australian regulatory authorities in 2004 (second largest market opportunity after the US).

Enzon has already started to market DepoCyt in the US and SKP expects to see wider usage of the drug by key oncologists in the next few months. Phase IV studies for the neoplastic meningitis indication are on track, with an FDA Advisory Committee meeting (ODAC) scheduled next month.

Overall, we expect the newsflow for SKP to continue and reiterate our BUY recommendation with a price objective of 80p (based on applying the speciality pharma multiple to our 06E EPS of 14p and discounting back agressively at 30% p.a.). Risks to the stock include the general risk of drug development delay and product approval failure.

Top Gun Trader, you are a very smart observer. That was spot on, very astute.
I wonder who it could be though, anyway. happy trading

Fingers crossed for blue,,bloomberg,,yes.

Who said 50 !!

Nice little profit that in & out in a few weeks result.

Good Morning.

Any bid for the company would have to be in the region of 65p with assets and pipeline products. Skyepharma now have the upper hand with Flutiform which places them in a very strong negotiating position, one is very surprised to see Skyepharma trading around 50p today; no doubt this will change and move forward through out this week. It has been rumoured that Merk and Pfizer are both interested in SKPs pipeline, but no doubt we will see other big names now appear on the scene Glaxo being one of them no doubt.

Please do your own research.

This is like 0.75p in old money.

Unbelievable mis-management...look at the sp fall like it's on a skydiving TV prog.
Grief it looks bad, very bad. ... 28.5pence.
(Execs should be paid 28p in the pound, at least they'd feel some pain.)

Psst if management is awake, still - get on with something to make some Money.

Oh deary, a Director buys a few hundred shares - wowie - that's a strong signal that things are very wrong still . . . . what exactly are they doing, I wonder? This is years after their original claims to be cutting edge and shareholter return-focus.
- Humm

yeeeeeeeeeeeeeeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa! lol

Still holding some of these from years back.

Forgot I still had these up 114% today can't be bad.

Flutiform Positive Outcome
http://www.moneyam.com/action/news/showArticle?id=4353278

Good finish 106% not bad.

SkyePharma soars on asthma drug approval

http://www.telegraph.co.uk/finance/markets/marketreport/9217584/SkyePharma-soars-on-asthma-drug-approval.html

It was 50p about five years ago when they were talking about this. that's equal to £50 now, due to 100 to 1 split!

How much does it worth now?

ahoj

Not Much.

Driver,
But you are holding these. What do you mean?
Can it be subject of a bid given its portfolio..?

ahoj

Not much, as I am only holding a few I bottom drawed these after the consolidation and didn’t top up, if it ten bags from here I might be interested.

I had 100k before consolidation, started adding again since the report. Finger crossed.

ahoj

Good luck, have a look at RGM,s news today Massive jorc.